Gilead

                                                                           

Gilead Sciences was founded in June 1987 by Michael L. Riordan, a medical doctor who was 29 years old at the time. 

Riordan graduated from Washington University in St. Louis, John Hopkins School Of Medicine 


The company's primary therapeutic focus was, and continues to be, in antiviral medicines, a field that interested Riordan because he contracted dengue, an untreatable viral disease, while working in malnutrition clinics as a Henry Luce Scholar  in the Phillipines.

                                                                        
                               Gilead Sciences: No 1 Pharmaceutical Company in Anti Virals

Primary Therapeutic Focus: HIV/AIDS and Liver Disease 

Product Breakdown: Hepatitis C 50 % and HIV 42 %

92 % Products in Anti Virals 

Tamiflu: Gilead Sciences

Tamiflu for Influenza 

Viral strains of Influenza are identified by their variation on H and N antigens

Viral Strains: Influenza A - Most Virulent

H1N1: Influenza A (Most Virulent)

Tamiflu (Neuraminidase Inhibitors)

First oral Neuraminidase inhibitor for Influenza A and Influenza B

Snapshot

Gilead and Antivirals